Mesothelioma
Philip Sporn Power Station and Asbestos Exposure
American Electric Power, working through its subsidiaries Appalachian Power Company and Ohio Power Company, constructed the Philip Sporn Plant in the late 1940s and early 1950s. The facility was named for Philip Sporn, the engineer who became president of AEP on May 22, 1947, and who led the company until his retirement in 1961. Sporn…
Read MoreRecent Studies Show Increase in Mesothelioma Among Younger Patients
For decades, mesothelioma has been viewed as a disease affecting older men, typically those who spent their careers in shipyards, construction sites, power plants, or manufacturing facilities where asbestos was widely used. Because of the disease’s long latency period, often 20 to 50 years between exposure and diagnosis, most patients are well into their 60s,…
Read MoreJohnson & Johnson Faces Talc Cancer Trial in Pennsylvania
A new talcum powder cancer trial has begun in the Philadelphia Court of Common Pleas, marking the second major mass tort case in the venue involving allegations that Johnson & Johnson’s iconic baby powder caused ovarian cancer. The lawsuit, brought by the estate of the late Gayle Emerson, claims that decades of talc use ultimately…
Read MoreFDA Withdraws Talc Asbestos Testing Rule, Raising Safety and Legal Concerns
FDA Withdraws Talc Asbestos Testing Rule, Raising Safety and Legal Concerns The recent decision by the Food and Drug Administration (FDA) to withdraw its proposed rule requiring standardized testing for asbestos in talc-based cosmetics has caused concerns among public health advocates, consumer protection organizations, and legal experts. For decades, asbestos contamination in talc has been…
Read MoreKeytruda’s New FDA Approval for Mesothelioma: A Breakthrough in Treatment
The U.S. Food and Drug Administration (FDA) has recently expanded the use of Keytruda (pembrolizumab), an immunotherapy drug, marking a significant advancement in the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Approved on September 17, 2024, the combination of Keytruda with pemetrexed and platinum-based chemotherapy offers new hope to mesothelioma patients, who…
Read More